Ernexa Therapeutics Inc Sustainability Reports
Ernexa Therapeutics Inc. develops innovative allogeneic cell therapies derived from induced pluripotent stem cells. The company focuses on discovering treatments for advanced cancers and autoimmune diseases, featuring its lead clinical candidate ERNA-101 for ovarian cancer.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
1 reports from 2025 to 2025
Company Profile
Ernexa Therapeutics Inc. develops innovative allogeneic cell therapies derived from induced pluripotent stem cells. The company focuses on discovering treatments for advanced cancers and autoimmune diseases, featuring its lead clinical candidate ERNA-101 for ovarian cancer.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
